Skip to Content

Yervoy (ipilimumab) Disease Interactions

There are 7 disease interactions with Yervoy (ipilimumab):

Major

Ipilimumab (Includes Yervoy) ↔ Dermatitis

Severe Potential Hazard, Moderate plausibility

Applies to: Allergies, Dermatitis Herpetiformis

Immune-mediated dermatitis, including fatal cases, have occurred with ipilimumab therapy. Monitor patients for signs and symptoms of dermatitis, such as rash and pruritus. Unless an alternate etiology has been identified, signs or symptoms of dermatitis should be considered immune-mediated. Permanently discontinue ipilimumab in patients with Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations. Withhold ipilimumab dosing in patients with moderate to severe signs and symptoms.

Major

Ipilimumab (Includes Yervoy) ↔ Endocrinopathies

Severe Potential Hazard, Moderate plausibility

Applies to: Hypothyroidism, Adrenal Insufficiency, Hyperthyroidism

Immune-mediated endocrinopathies, including fatal cases, have occurred with ipilimumab therapy. Monitor clinical chemistries, adrenocorticotropic hormone (ACTH) level, and thyroid function tests at the start of treatment, before each dose, and as clinically indicated based on symptoms. Withhold ipilimumab dosing in symptomatic patients and consider referral to an endocrinologist.

Major

Ipilimumab (Includes Yervoy) ↔ Enterocolitis

Severe Potential Hazard, Moderate plausibility

Applies to: Infectious Diarrhea/Enterocolitis/Gastroenteritis, Inflammatory Bowel Disease

Immune-mediated enterocolitis, including fatal cases, have occurred with ipilimumab therapy. It is recommended to withhold ipilimumab dosing in patients with moderate enterocolitis and institute appropriate measures. Ipilimumab must be permanently discontinued in patients with severe enterocolitis and appropriate measures should be initiated.

Major

Ipilimumab (Includes Yervoy) ↔ Ocular Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Visual Defect/Disturbance

Permanently discontinue ipilimumab in patients with immune-mediated ocular disease that is unresponsive to local immunosuppressive therapy.

Moderate

Ipilimumab (Includes Yervoy) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The effect of hepatic impairment on the clearance of ipilimumab was evaluated in patients with mild hepatic impairment. No clinically important differences in the clearance of ipilimumab were found between patients with mild hepatic impairment and patients with normal hepatic function. Ipilimumab has not been studied in patients with moderate or severe hepatic impairment.

Moderate

Ipilimumab (Includes Yervoy) ↔ Hepatitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Autoimmune Hepatitis

Immune-mediated hepatitis, including fatal cases, has occurred with ipilimumab therapy. In patients with hepatotoxicity, rule out infectious or malignant causes and increase frequency of liver function test monitoring until resolution. Ipilimumab must be permanently discontinued in patients with Grade 3 to 4 hepatotoxicity and appropriate measures should be taken. Withhold ipilimumab in patients with Grade 2 hepatotoxicity.

Moderate

Ipilimumab (Includes Yervoy) ↔ Neuropathies

Minor Potential Hazard, High plausibility

Applies to: Autonomic Neuropathy, Guillain-Barre Syndrome

Immune-mediated neuropathies, including fatal cases, have occurred with ipilimumab therapy. Ipilimumab must be permanently discontinued in patients with severe neuropathy (interfering with daily activities) such as Guillain-Barré-like syndromes and appropriate measures should be initiated. Withhold ipilimumab dosing in patients with moderate neuropathy (not interfering with daily activities).

Yervoy (ipilimumab) drug Interactions

There are 134 drug interactions with Yervoy (ipilimumab)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide